BioSpace News Archive

Lysogene announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its LYS-SAF302 program for the treatment of mucopolysaccharidosis Type IIIA.

LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesday, March 3, 2020. The time has been revised to 12:00 noon Greenwich Mean Time (GMT) / 7:00 am Eastern Standard Time (EST) / 8:00 pm Hong Kong Time (HKT). Due to travel restrictions resulting from the novel coronavirus outbreak, Chi-Med managem

Hansa Biopharma has been invited to participate in two global biotech and healthcare conferences during March including Cowen Annual Health Care Conference in Boston and Carnegie Nordic Healthcare Seminar in Stockholm

STOCKHOLM , Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC) , shows that t

Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday March 2, 2020, at 14:00 to 16:30 CET.

The Ethisphere Institute recognized 3M for ethics and integrity in business conduct and compliance for the seventh straight year.

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), the third largest provider of home medical equipment (“HME”) in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2019.

Liam Kelly, President and Chief Executive Officer, Teleflex Incorporated, is scheduled to speak at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida, on Tuesday, March 10, 2020 at 9:00 am.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to report that a total of 6,289,851 of the common share purchase warrants issued on February 10 and February 21, 2017 in a non-brokered private placement were exercised at a price of $0.20 per share for gross proceeds of $1,257,970,

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial Officer.